Incyte said it recorded net income of $597.6 million ($2.65 per diluted share) for the fiscal year ended December 31, 2023, compared with $340.7 million ($1.52 per diluted share) for 2022.

1. 01

   Incyte said it recorded net income of $597.6 million ($2.65 per diluted share) for the fiscal year ended December 31, 2023, compared with $340.7 million ($1.52 per diluted share) for 2022.

2. 02

   The company said the increase in JAKAFI product revenues from 2022 to 2023 consisted of a volume increase of $135.3 million and a price increase of $49.2 million.

3. 03

   The company sued CMS, arguing that its rule on the definition of "line extension" for the Medicaid rebate program treats OPZELURA as a line extension of JAKAFI. It said it had accrued approximately $59.5 million in incremental rebates within accrued and other current liabilities as of December 31, 2023.

4. 04

   The company said it had cash, cash equivalents and marketable securities of $3.7 billion as of December 31, 2023, and no outstanding borrowings under its $500.0 million revolving credit facility.

Key figures

Fiscal year ended December 31, 2023

Revenue

$3.7B

Operating income

$621M

Net income

$598M

EPS

$2.65

Operating cash flow

$496M

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.